Needham & Company LLC reaffirmed their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a report issued on Monday, December 23rd, AnalystRatings.com reports. They currently have a $84.00 price objective on the stock.
A number of other research analysts have also recently weighed in on CRSP. BidaskClub cut Crispr Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, December 13th. William Blair upgraded Crispr Therapeutics from a market perform rating to an outperform rating in a research report on Tuesday, November 19th. Oppenheimer lifted their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a research report on Monday, November 25th. Chardan Capital reiterated a buy rating and set a $72.50 price objective on shares of Crispr Therapeutics in a research report on Monday, November 18th. Finally, Wells Fargo & Co reiterated a buy rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the stock. Crispr Therapeutics has an average rating of Buy and a consensus target price of $71.38.
Shares of NASDAQ CRSP traded up $0.07 during midday trading on Monday, hitting $59.63. The stock had a trading volume of 821,298 shares, compared to its average volume of 1,138,700. The business’s 50 day moving average is $65.50 and its 200-day moving average is $52.02. The company has a market cap of $3.29 billion, a P/E ratio of -17.33 and a beta of 3.20. Crispr Therapeutics has a 52 week low of $29.34 and a 52 week high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. As a group, analysts expect that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. NEXT Financial Group Inc lifted its holdings in shares of Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the last quarter. Benjamin Edwards Inc. grew its position in shares of Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after purchasing an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. acquired a new position in shares of Crispr Therapeutics in the third quarter valued at approximately $26,000. Farmers & Merchants Trust Co of Chambersburg PA acquired a new position in shares of Crispr Therapeutics in the fourth quarter valued at approximately $26,000. Finally, Webster Bank N. A. acquired a new position in shares of Crispr Therapeutics in the fourth quarter valued at approximately $26,000. 49.82% of the stock is owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Forex
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.